Chemoradiation with raltitrexed (TOMUDEX) in preoperative treatment of stage II-III resectable rectal cancer: A phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 1, 2004, Pages 130-138

  Gambacorta, Maria Antonietta ^a   Valentini, Vincenzo ^a,d   Morganti, Alessio Giuseppe ^a   Mantini, Giovanna ^a   Miccichè, Francesco ^a   Ratto, Carlo ^a   Di Miceli, Dario ^a   Rotondi, Fabio ^a   Alfieri, Sergio ^a   Doglietto, Giovan Battista ^a   Vargas, Jose Garcia ^b   De Paoli, Antonino ^c   Rossi, Carlo ^c   Cellini, Numa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ASTRAZENECA   (United Kingdom)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Preoperative chemoradiation; Raltitrexed; Rectal carcinoma

Indexed keywords

CHEMORADIATION; RECTAL CARCINOMA;

CARCINOGENS; CHEMOTHERAPY; DIAGNOSIS; PATHOLOGY; TOXICITY; TUMORS;

RADIOTHERAPY;

RALTITREXED;

ADULT; AGED; ANEMIA; ANUS SPHINCTER; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL ISOLATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIAGNOSTIC VALUE; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; ERYTHEMA; FEMALE; FOLLOW UP; GAMMA IRRADIATION; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROCTITIS; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; SKIN EXFOLIATION; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR REGRESSION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; FOLIC ACID; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; THIOPHENES;

EID: 4444282068     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.02.003     Document Type: Article

References (46)

1. Coia L.R., Hanks G.E. The role of adjuvant radiation in the treatment of rectal cancer. Semin Oncol. 18:1991;571-584
2. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 324:1991;709-715
3. Tepper J.E., O'Connell M.J., Petroni G.R., et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer Initial results of Intergroup 0114. J Clin Oncol. 15:1997;2030-2039
4. O'Connell M.J., Martenson J.A., Wieand H.S. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507
5. UICC International Union Against Cancer. TNM classification of malignant tumors. 4th ed, 2nd revision:1992;Springer-Verlag, Berlin
6. International Commission on Radiation Units and Measurements. ICRU Report 50 Prescribing, recording and reporting photon beam therapy. 1993;ICRU, Bethesda
7. Capirci C., Polico C., Mandoliti G. Dislocation of small bowel volume within box pelvic treatment fields, using new "up down table" device. Int J Radiat Oncol Biol Phys. 51:2001;465-473
8. Machover D., Schwarzenberg L., Goldschmidt E., et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid A pilot study. Cancer Treat Rep. 66:1982;1803-1807
9. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting result of cancer treatment. Cancer. 47:1981;207-214
10. Perez C.A., Brady L.W. Overview. Perez C.A., Brady L.W. Principles and practice of radiation oncology. 2nd ed:1992;1-62 Lippincott, Philadelphia
11. Valentini V., Coco C., Cellini N., et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer Acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys. 40:1998;1067-1075
12. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression grade after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 73:1994;2680-2686
13. Wheeler JMD, Warren BF, Mortesen NJMCC, et al. Quantification of histologic regression of rectal cancer after irradiation. Dis Colon Rectum 2002;45,8:1051-1056
14. Lawrence T.S., Tepper J.E., Blackstock A.W. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol. 7:1997;260-266
15. Steel G.G. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol. 11:1988;31-53
16. Vietti J., Eggerding F., Valeriote F. Combined effect of X radiation and 5-fluorouracil on survival of transplanted leukemic cells. J Natl Cancer Inst. 47:1971;865-870
17. Byfield J.E., Calabro-Jones P., Klisak I., et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X-rays. Int J Radiat Oncol Biol Phys. 8:1982;1923-1933
18. Byfield J.E., Frankel S.S., Sharp T.R., et al. Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation. Int J Radiat Oncol Biol Phys. 11:1985;791-800
19. Byfield J.E. Theoretical basis and clinical applications of 5-fluorouracil as a radiosensitizer - An overview. Rotman M., Rosenthal C.J. Concomitant continuous infusion chemotherapy and radiation. 1991;115-127 Springer-Verlag, Berlin
20. Teicher B.A., Ara G., Chen Y., et al. Interaction of Tomudex with radiation in vitro and in vivo. Int J Oncol. 13:1998;437-442
21. Anderson N., Lokich J. Controversial issues in 5-fluorouracil infusion use Dose intensity, treatment duration and cost comparisons. Cancer. 70:1992;998-1000
22. Martenson J.A., Shanahan T.G., O'Connell M.J., et al. Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy. Cancer. 86:1999;710-714
23. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capacitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1998;1274-1281
24. Sawada N., Ishikawa T., Sekiguchi F., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capacitabine (Xeloda) in human cancer xenograft. Clin Cancer Res. 5:1999;2948-2953
25. Budman D.R., Meropol N.J., Reigner B., et al. Preliminary studies of a novel oral fluoropyrimidine carbamate Capacitabine. J Clin Oncol. 16:1998;1795-1802
26. Xeloda Colorectal Cancer Study Group, Twelves C., Boyer M., Findlay M., et al. Capacitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal cancer. Eur J Cancer. 37:2001;597-604
27. Dunst J., Rees T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capacitabine in rectal cancer. J Clin Oncol. 20:2002;3983-3991
28. Zalcberg J, Ngan S, Michael M, et al. Observed toxicities in a phase I study of preoperative radiotherapy combined with capacitabine for locally advanced potentially resectable rectal cancer [Abstract]. Proceedings 27th ESMO Congress, Nice, France, Oct 18-22, 2002
29. Kim J.S., Cho M.J., Song K.S., et al. Preoperative chemoradiation using oral capacitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 54:2002;403-408
30. Yoon W., Choi J., Kim J., et al. Enhanced tumoricidal effect of preoperative chemoirradiation using capacitabine for locally advanced rectal cancer. [Abstract] Proc Am Soc Clin Oncol. 20:2001;1046
31. Hoff P.M., Janjan N., Saad E.D., et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol. 18:2000;3529-3534
32. Schiebe M.E., Reese T., Wenz F., et al. Phase I trial of oral uracil and tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer. Anticancer Drugs. 13:2002;1105-1109
33. de la Torre A., Ramos S., Varcarcel F.J., et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 45:1999;629-634
34. Feliu J., Calvillo J., Escribano A., et al. Neoadjuvant therapy of rectal carcinoma with UFT-folinic acid (LV) plus radiotherapy (RT). [Abstract] Proc Am Soc Clin Oncol. 18:1999;239a
35. Calvo F.A., Gómez-Espí M., Diaz-Gonzales J.A., et al. Pathologic downstaging of T3-4,Nx rectal cancer after chemoradiation 5-fluorouracil vs. tegafur. Int J Radiat Oncol Biol Phys. 51:2001;1264-1270
36. Jackman A.L., Taylor G.A., Gibson W., et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo A new agent for clinical study. Cancer Res. 51:1991;5579-5586
37. Jackman A.L., Calvert A.H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol. 6:1995;871-881
38. James R., Price P., Valentini V. Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer Preliminary results of phase I studies. Eur J Cancer. 35:(Suppl. 1):1999;S19-S22
39. Valentini V., Doglietto G.B., Morganti A.G., et al. Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers A phase I study. Eur J Cancer. 37:2001;2050-2055
40. Valentini V., Coco C., Cellini N., et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer Acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys. 40:1998;1067-1075
41. Valentini V., Coco C., Cellini N., et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer Acute toxicity, tumor response and sphincter preservation. Int J Radiat Oncol Biol Phys. 45:1999;1175-1184
42. Valentini V., Coco C., Cellini N., et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer Acute toxicity, tumor response and sphincter preservation in three-year consecutive studies. Int J Radiat Oncol Biol Phys. 51:2001;371-383
43. Vecchio F.M., Valentini V., Padula G., et al. A pathologic score system after preoperative combined modality therapy as a predictor of metastases free survival in the management of rectal carcinoma. [Abstract] Int J Radiat Oncol Biol Phys. 542:2002;207
44. Rich T.A., Skibber J.M., Ajani J.A., et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 32:1995;1025-1029
45. Chari R.S., Tyler D.S., Anscher M.S., et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg. 221:1995;778-786
46. Grann A., Minsky B.D., Cohen A.M., et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum. 40:1997;515-522